SUMMARY -Luminal B (HER2 negative) subtype is the most diversiform type of breast cancers, with a high Ki-67 proliferation index (>20%) or/and low progesterone (PR; <20%) with various intensity and distribution of hormone receptors. Considerable diff erence has also been noticed in disease outcome, wherefore there is the need for a more detailed classifi cation of this tumor subtype. Th e clinical and pathologic parameters of 147 luminal B (HER2 negative) breast cancers were examined. Th e expression of hormone receptors in correlation with other prognostic factors and disease outcome was analyzed by Kaplan-Meier curves and multivariate Cox regression analysis. Th e KaplanMayer analysis showed that low positivity of estrogen (ER) and PR receptors in tumors was associated with a signifi cantly worse disease outcome (overall survival (ER), p=0.020; disease free survival (ER), p=0.019; overall survival (PR), p=0.026; disease free survival (PR), p=0.038)), unlike Ki-67, which did not show a statistically signifi cant connection (overall survival, p=0.343; disease free survival, p=0.322). Th e intensity of receptor staining and Ki-67 relative to other histopathologic prognostic factors showed a statistically signifi cant correlation solely with histologic grade of tumor. By using the Cox regression model, PR proved to be an independent prognostic factor for overall survival (p=0.004) and disease free survival (p=0.029). Th e luminal B (HER2 negative) breast cancer with low expression of hormone receptors, independent of the Ki-67 proliferation index, and in correlation with a higher histologic grade, could be a unique subtype of cancer.
Introduction
Breast cancer is still the most common malignant tumor in women and a signifi cant healthcare issue 1 . As it is well known, breast cancer is a heterogeneous disease 2 , the course and outcome of which is assessed by prognostic parameters including tumor size, histologic grade, histologic subtype and lymph node involvement, along with estrogen (ER) and progesterone (PR) receptor expression 3 . Diff erent breast cancer classifi cations use these parameters to most accurately assess disease outcome and modify oncologic therapy by the more individualistic approach. However, the most recent molecular research has attributed a new classification that divides breast cancer into 4 subtypes (luminal A, luminal B, HER2 positive and basal-like). Th is classifi cation was accepted at the 12 th St. Gallen International Breast Cancer Conference held in 2011, and it is now widely used. Th e classifi cation itself is based primarily on the expression of single gene groups (expression of ER and PR in luminal subtypes or HER2 and proliferation gene groups in basal-like and HER2 positive subtypes), although the fi nancially more acceptable and accessible immunohistochemical interpretation of ER, PR and HER2 receptors, as well as Ki-67 proliferation index, which are needed to place the tumor in a precise group, has been accepted as an appropriate replacement method. By using the immunohistochemistry method, breast cancers are also classifi ed into four groups: luminal A, luminal B, HER2 positive and triple negative 4 . Th e hormone positive tumors fall into the category of luminal A or luminal B subtypes, mostly dependent on the Ki-67 proliferation index, which is higher in the luminal B subtype. At the 13 th St. Gallen Consensus Conference held in 2013, a cut-off value of 20% was proposed for Ki-67; using it, tumors with higher values are placed into luminal B subtype, as well as those tumors that have weaker expression (less than 20%) of ER or PR, in addition to tumors that have one negative receptor 5 . Luminal A subtype cancer have better and more favorable outcome and it is also well known that they have better response to hormonal therapy than luminal B cancers; in fact, it is the most heterogeneous subtype of breast cancer. Th e Ki-67 proliferation index has a considerable range in this subtype of cancer (20%-100%), but even more diversiform is the positivity span of hormones that can diff er from only focal mild positivity in a single tumor cell to diff use intensive positivity in all tumor cells 6 . Given that the heterogeneity of this tumor subtype is also refl ected in disease outcome 7 , the question arises whether the luminal B (HER2 negative) population with lower Ki-67 proliferation index and more intensive and diff use positivity of receptors is the one that is more similar to the luminal A subtype (with better prognosis), both by response to hormone therapy and less aggressive behavior, and whether this group of luminal B (HER2 negative) cancers can be divided into subgroups of those with better and worse outcomes (by immunohistochemical assessment of ER, PR and Ki-67 and in correlation with the common prognostic parameters).
Unlike other prognostic parameters (lymph node status, tumor grade, lymphovascular invasion), the role of which in the assessment of tumor behavior and thus the appropriate therapeutic guideline is relatively distinct, the level of tumor positivity needed for inclusion of endocrine therapy in ER positive tumors is still partly unclear. Should tumors with high positivity stains, with proved better outcome receive adjuvant chemotherapy, is also a question that should be answered 8 . Th is study included 147 luminal B (HER2 negative) breast cancers that were determined by immunohistochemical analysis of ER, PR, HER2 and Ki-67 proliferation index, in order to establish the connection of usual prognostic parameters with hormone receptor staining intensity and percentage of positive cells, along with Ki-67 proliferation index, in correlation with clinical outcome (overall survival (OS) and disease free survival (DFS)). Th e immunohistochemical analysis was performed on formalin fi xed, paraffi n embedded tissue on a Ventana automated slide stainer. Th e following rabbit monoclonal primary antibodies were used: Confi rm anti-estrogen receptor (ER) (clone SP1), Confi rm anti-progesterone receptor (PR) (clone 1E2), Confi rm anti-Ki-67 (clone 30-9) and Pathwayanti HER-2/neu (clone 4B5). Th ese antibodies were optimally diluted for use with the Ventana ultra VIEW Universal DAB detection kit. Th e slides were evaluated under a light microscope by two independent pathologists.
Material and Methods
To determine the ER and PR receptor status, scoring by the method proposed by Allred et al. was used 9 .
Percentage of positive cells (0 = no positive cells; 1=<1%; 2=1%-10%; 3=11%-33%; 4=34%-66%; and 5=>67% of positive cells) and intensity (0 = none; 1 = weak; 2 = intermediate; and 3 = strong intensity) were added, yielding a score of 0-8. HER-2 immunostaining was graded as follows: 0, 1+, 2+, and 3+. Intensity scores of 0 or 1+ were designated as negative expression and 3+ as positive expression for HER2/neu. Th e 2+ score was further subjected to silver-enhanced in situ hybridization (SISH) analysis.
Th e Ki-67 proliferation index was measured according to the recommendations from the International Ki-67 in the Breast Cancer Working Group 10 .
Histologic classifi cation of tumor specimens was based on the World Health Organization criteria 11 , and tumors were graded according to the ScarffBloom Richardson classifi cation as modifi ed by Elston and Ellis 12 . Tumor size was divided into four groups (>0.5≤1.0 cm; >1≤2 cm; >2≤5 cm; and >5 cm) and lymph node status into four groups, as follows: N0 (negative lymph node); N1 (1-3 positive nodes); N2 (4-9 positive nodes); and N3 (>10 positive nodes).
Demographic and clinical features of the patients were obtained from hospital charts. Patients having a metastatic disease at presentation were excluded. DFS was determined as the period without locoregional or distant recurrence. Locoregional recurrence was defi ned as a tumor occurring at the resection site and distant recurrence was defi ned as a tumor outside the site of resection including the liver, adrenals, lungs or bones. Th e recurrence was diagnosed by radiologic image or biopsy.
Statistical analysis
Th e data collected were statistically analyzed using the MedCalc Statistical Software version 16.4.2 (MedCalc Software bvba, Ostend, Belgium; https:// www.medcalc.org; 2016). Th e survival time was calculated in months starting from the date of the surgery. Fisher exact test for categorical data was used to analyze any relationship between the clinical and histopathologic factors. Survival analysis of censored data was performed using the Kaplan-Meier method. Th e log-rank test was used to compare survival data curves. Th e univariate and multivariate stepwise proportional-hazard analysis (Cox model) was performed to identify the variables signifi cantly associated with survival. Cut-off values were defi ned using the ROC analysis.
Categorical data were expressed as absolute and relative frequencies, whereas numerical data and scores were expressed with median and interquartile range. Th e level of statistical signifi cance was set at p<0.05.
Results
In the study sample, the median age was 62 (53-70), range 33 to 83 years. Most of the tumors, 102 (69.38%) were diagnosed as not otherwise specifi ed (NOS), whereas 22 (14.96%) were invasive lobular cancers and 23 (15.66%) were pooled as 'other types' in this study. As many as 128 (87.00%) cases were well or moderately diff erentiated (grade 1 and 2), and only 19 (13.00%) were poorly diff erentiated (grade 3). Lymph node metastases were recorded in 55.10% of study patients (Table 1) . Signifi cantly, most of the tumors were >2≤5 cm in size (Table 1) .
Th e median follow up period was 80.7 months with the interquartile range of 35.7-103.5 months and total range of 1.9-128.2 months. During the study period, 53 (36.1%) patients died. Recurrences were reported in 45 (30.7%) patients, as follows: local recurrences in 7 (4.8%) and distant recurrences in 38 (25.9%) cases.
In this group of patients, there were no ER negative tumors, 9 tumors were PR negative, and another 8 tumors had less than 20% of PR positive staining cells. All of these tumors had Ki-67 proliferation index above 20%.
Th e ER and PR scores, as well as Ki-67 proliferation index were signifi cantly correlated with tumor grade (ER p=0.037; PR p=0.008; and Ki-67 p<0.001). However, ER and PR scores along with Ki-67 proliferation index were not associated with other parame- (Fig. 1) .
Univariate and multivariate Cox analysis was performed, including age, ER/PR score and Ki-67 proliferation index (Tables 5 and 6 ). For OS and DFS, PR was found to be a statistically signifi cant independent prognostic parameter (OS p=0.004; and DFS p=0.029), while age was statistically correlated with OS (p<0.001). In this analysis, neither ER nor Ki-67 proliferation index seemed to have an independent role in OS and DFS.
Discussion
Luminal B (HER2 negative) subtype of breast cancer, as defi ned at the last 2015 St. Gallen Consensus in Vienna 2015 5 , is the most heterogeneous type of breast cancer compared to other subtypes determined by molecular gene profi ling. As it is known, apart from previously listed histopathologic and molecular char- 
Fig. 1. Kaplan-Meier survival analysis of estrogen (ER), progesterone (PR) and Ki-67.
acteristics, certain clinical characteristics are featured in this group, including worse relapse free survival, an increased risk of early relapse, predisposition to bone and pleural relapse, relative insensitivity to endocrine therapy (in comparison to luminal A subtype) and relative insensitivity to chemotherapy (in comparison to basal-like subtype) 8 . Sørlie et al. showed in their research that breast cancer could be divided into certain groups based on molecular profi ling of genes, and they introduced a new concept of luminal C carcinoma as a distinct subtype that is linked with the worst outcome 13 . Th e expression of numerous genes, otherwise characteristic of basal-like and HER2 positive cancers, has been noticed in this subtype of cancer, in addition to ER and PR expression.
Recent researches of luminal B cancers, which show weaker intensity on hormone receptor staining or negative staining for one of the hormones, are also of great interest. Th us, Gloyeske et al. proved in their work that luminal B type with low ER intensity resembled the basal-like cancer morphologically, as well as by the degree of chemotherapy response 14 . Park et al. presented a group of cancers that were negative for one of the hormone receptors as a subgroup of luminal B (HER2 negative) cancers with worse prognosis 15 . It has also been demonstrated that luminal B subtype with low expression of ER has poorer complete pathologic response to neoadjuvant therapy, as compared with cancers with high expression. Th e response to neoadjuvant therapy is very much alike that of ER negative tumors, however, only in the group of luminal B HER2 negative subtype 16 . Dvorkin-Gheva and Hassell found, by molecular profi ling of genes in diverse breast cancers, that there were 35% of those that could not be placed in any of 17 . Th is subtype distinctly diff ers from the aforementioned luminal C subtype and, even though they have a low degree of HER2 amplifi cation, the transcription profi les of genes similar to luminal A and B tumors were established in about 25% of cases. Clinical follow up established that this group of patients had better outcome than the basal-like subtype, although worse than the luminal A subtype. In daily routine, a large proportion of these tumors are certainly categorized using immunohistochemical methods as the luminal B (HER2 negative) subtype, and possibly these being the ones that show lower hormone expression rate along with poorer prognosis and disease outcome.
Th rough Kaplan-Meier curves, a statistically signifi cant connection was found between lower ER and PR expression rate and worse disease outcome (OS and DFS), which is in accordance with recent researches and favors the distinct subtype of luminal B (HER2 negative) cancers that express lower hormone positivity and have a more aggressive course.
In their meta-analysis, the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) proved that tamoxifen improved relapse free survival in ER positive tumors, independently of the PR status. On the other hand, Cancello et al. showed an interconnection of the negative PR receptors with a higher risk of disease relapse 18 . Furthermore, Zong et al. showed that the luminal B (HER2 negative) tumors had an increased risk of disease relapse when PR receptors were negative, even with well-conducted endocrine and adjuvant chemotherapies 19 . Using multivariate Cox regression analysis, in this study, a statistically signifi cant impact of PR intensity on OS and DFS was established, implying the importance of negative or low positive PR expression as the isolated criterion in the assessment of disease outcome.
Th e American Society of Clinical Oncology and the College of American Pathologists (ASCO/CAP) have proposed that ER status should be considered positive if 1% or more tumor cells express nuclear positivity by immunohistochemical staining. Additionally, they suggest semiquantitative evaluation of immunohistochemical staining results (H-score or Allred method) 20 . It is well known that hormone therapy is applied in tumors with positive hormone receptors, however, only some patients with positive hormone receptors receive additional chemotherapy, mostly depending on the tumor biological characteristics 21 . Recent studies additionally demonstrate clinical importance of semiquantitative evaluation of hormone receptors, arguing that tumors with lower expression of hormone receptors can be, in addition to other parameters, a criterion for the introduction of chemotherapy 22 . From this, it can be concluded that hormone receptor staining and percentage of positive staining cells is an important prognostic parameter in luminal B (HER2 negative) breast cancer. Furthermore, it can be concluded that the groups with lower intensity of positive hormone receptors, as well as those with one negative receptor can be placed into a unique group of luminal B (HER2 negative) breast cancer, based on the proven worse disease outcome and independently of most of the usual prognostic parameters.
Th e Ki-67 proliferation index is acknowledged as being important for distinction between luminal A and luminal B subtypes of cancer, in addition to estimation of a more aggressive disease course. In the given study group, all tumors had Ki-67 value >20%. Th ere were 17 tumors that had negative or low (<20%) percentage of PR positive cells, yet all of these tumors had high Ki-67 proliferation index, and nevertheless had to be placed in the luminal B subtype. However, the Ki-67 proliferation index value had no impact on disease outcome in the presented group of patients and did not appear as a relevant factor regarding disease outcome.
Th e present study showed, by correlation analysis of ER and PR values and Ki-67 index with other clinical and pathologic parameters, a statistically significant correlation solely with tumor grade. Tumors with lower ER and PR intensity and higher Ki-67 proliferation activity were of a statistically signifi cantly higher grade. Considering these results, it is concluded that in the group of tumors with weaker hormone positivity and those with higher Ki-67 proliferation activity, the histologic grade of the tumor can be a significant parameter when more aggressive oncologic therapy is to be determined (in regard to other parameters including tumor size or axillary lymph node involvement).
Accordingly, besides molecular analyses and delicate gene profi ling (which is unquestionably becoming necessary in the near future for malignant tumor diagnosis and analysis), the basic pathologic examination of tumor tissue remains a highly useful method, along with precise assessment of the parameters (percentage of tubule formation, degree of nuclear pleomorphism and accurate mitotic count) needed for tumor grading.
Finally, we conclude that the luminal B (HER2 negative) breast cancers with low hormone expression and independent of the Ki-67 proliferation index, might be a separate tumor group, and thus candidates for a more aggressive oncologic therapy. Independently of the new, modern methods of gene profi ling, the old practice of histopathologic assessment of tumor grade and hormone receptor intensity, as well as the semiquantitative evaluation of ER and PR expression in tumor tissue are still essential in daily routine.
For better individual modifi cation of oncologic therapy, the luminal B (HER2 negative) breast cancers should be additionally researched, and receptor intensity in this group of cancers could be an additional factor for adjuvant chemotherapy administration.
